Several studies have demonstrated that PPARγ agonist, thiazolidinedione, a class of anti-diabetic drugs including rosiglitazone and troglitazone, significantly inhibit primary tumor growth and metastasis in a variety of cancers including colon, breast, prostate, brain and lung [11-15]. This evidence concerns the gene PPARG and cancer.